Slide 1: Q1 2025 Earnings Presentation
Q1 2025 Earnings Presentation May 1, 2025 Q1 2025 Earnings Presentation FMC CORPORATION 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain statements made in this presentation are forward- looking statements that are based on our current views and assumptions regarding future events, future business conditions and the outlook
Slide 3: 2025 Focus Areas
2025 Focus Areas • Correct FMC inventory in the channel to align with customer target levels Align inventory • Expect to be completed by end of Q2 in all regions excluding Asia • Implement strategy for Rynaxypyr® active Rynaxypyr® • Take advantage of lower manufacturing costs to grow solo formulatio
Slide 4: Q1 2025 Results
Q1 2025 Results Q1 2025 Q1 2024 2025 VS. 2024 Revenue $791 $918 (14)% GAAP Net Income (Loss) $(16) $(3) $(13) Adjusted EBITDA1 $120 $161 (25)% % Revenue 15.1% 17.5% (240) bps GAAP EPS $(0.12) $(0.02) $(0.10) Adjusted EPS1 $0.18 $0.36 (50)% Note: Amounts in millions of USD except for EPS Q1 2025 HIGH
Slide 5: Q1 2025 Regional Revenue Drivers
Q1 2025 Regional Revenue Drivers Revenue down 10 percent organically1 REGIONAL REVENUE BRIDGE North $186 million Latin $207 million (-28% YOY, (10% YOY, America -27% ex-FX) America 17% ex-FX) $918 $19 $791 • Lower volume due to cautious • Volume growth driven by increased ($73) ($39) ($34) purchasin
Slide 6: Q1 2025 Adjusted EBITDA Drivers
Q1 2025 Adjusted EBITDA1 Drivers Adjusted EBITDA1 down 25% Adjusted EBITDA1 BRIDGE $161 ($7) $63 $120 ($17) ($80) Q1 '24 Volume, Mix, Launches Price Cost FX Q1 '25 Note: Amounts in millions of USD KEY DRIVERS AT A GLANCE Volume, Mix, Launches Cost • Prudent sales into the channel in many countries a
Slide 7: Q2 2025 Financial Outlook
Q2 2025 Financial Outlook Q2 2024 Q2 2025 Guidance REVENUE DRIVERS • Modest increase in volume as prudent sales into channel continues REVENUE $1.04 $940 million – • Price decline in low-to-mid single digits primarily from contract adjustments to specific diamide partners billion $1.10 billion • Low
Slide 8: FY 2025 Financial Outlook
FY 2025 Financial Outlook FY 2024 FY 2025 Guidance REVENUE DRIVERS • Higher volume as increase in growth portfolio • Low-to-mid single digit price decline REVENUE $4.15 billion – offsets channel correction actions taken in many Includes adjustments in certain “cost-plus” $4.25 $4.35 billion countr
Slide 9: Evolving Tariff Environment
Evolving Tariff Environment Tariffs initially implemented on imports from China in 2018/2019 already included in FMC’s ongoing Section 301 cost structure. Tariff IEEPA Tariffs implemented under International Emergency Economic Powers Act (IEEPA) that were Types (Initial) announced in February and Ma
Slide 10: Recent Tariffs and Expected Impact to FMC Materials
Recent Tariffs and Expected Impact to FMC Materials Estimate $15 million – $20 million of direct incremental costs in 2025 IEEPA Drawback IEEPA Drawback IEEPA TOTAL Exemptions Exemptions (Before exemptions and (Initial) Eligible? (Reciprocal) Eligible? drawback) CHINA TO US Annex II 20% No No 0% N/A
Slide 11: H2 Adjusted EBITDA Versus Prior Year
H2 Adjusted EBITDA1 Versus Prior Year Growth Expected in H2 from Favorable Costs and Higher Sales of New Products $60 - $70 $90 - $100 $600 $540 $(95) – $(105) 1 1 H2 2024 Adj. EBITDA Volume, Mix, Launches Price & FX Cost H2 2025 Adj. EBITDA KEY DRIVERS AT A GLANCE Volume, Mix, Launches Cost • Launc
Slide 12: Q1 Cash Results and 2025 Cash Flow Guidance
Q1 Cash Results and 2025 Cash Flow Guidance $614M $300M 1 1 2 1 2024 FCF Adj. EBITDA Working Capital, Other CFO Capex Disc. Ops. 2025 FCF Q1 ’25 In Millions Q1 ‘25 Q1 ‘24 FY 2025 Guidance vs. Q1 ’24 Adjusted EBITDA1 $120 $161 $(41) $870 - $950 Cash from Operations (GAAP) $(545) $(143) $(402) $400 -
Slide 13: Q1 2025 Earnings Presentation FMC CORPORATION
Q1 2025 Earnings Presentation FMC CORPORATION 13
Slide 14: Protection Timelines for Cyazypyr Active in Key Markets
Protection Timelines for Cyazypyr® Active in Key Markets 2025 2026 2027 2028 Highlights • Key solo formulations have patent Patented Mixtures and Formulations protection extending beyond 2028 in Patent Protection| Key Process certain markets, for example Exirel® EUROPE Steps and Intermediate Compoun
Slide 15: Modeling Assumptions for 2025
Modeling Assumptions for 2025 Appendix $210 million – 13 – 15 $1 million – $2 Revenue: ($110) million EBITDA: ($25) million $230 million percent million INTEREST EXPENSE NON-CONTROLLING INTEREST 2025 EXPECTED GSS LOSS OF ADJUSTED TAX RATE1 CONTRIBUTION ~125.6 $175 million – $200 million – $105 – $11
Slide 16: Q1 2025 Adjusted EPS Variance
Q1 2025 Adjusted EPS1 Variance Appendix $0.36 $(0.28) $0.08 $0.01 $0.01 $0.18 Q1 ‘24 Adj. EBITDA1 INT. EXPENSE D&A OTHER Q1 ‘25 1. Denotes non-GAAP financial term. Refer to non-GAAP financial terms at the beginning of this presentation Q1 2025 Earnings Presentation FMC CORPORATION 16
Slide 17: Additional Disclaimers
Additional Disclaimers Always read and follow all label directions, restrictions and precautions for use. Products listed here may not be registered for sale or use in all states, countries or jurisdictions. No offer for sale, sale, or use of any such products is permitted prior to the issuance of t
Slide 18: Q1 2025 Earnings Presentation FMC CORPORATION
Copyright © 2025, FMC Corporation. All Rights Reserved. Q1 2025 Earnings Presentation FMC CORPORATION 18